- Home
- CKPT vs CRNC Comparison
CKPT vs CRNC Comparison
Compare CKPT & CRNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- CRNC
- Stock Information
- Founded
- CKPT 2014
- CRNC 2020
- Country
- CKPT United States
- CRNC United States
- Employees
- CKPT N/A
- CRNC N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- CRNC EDP Services
- Sector
- CKPT Health Care
- CRNC Technology
- Exchange
- CKPT Nasdaq
- CRNC Nasdaq
- Market Cap
- CKPT 151.9M
- CRNC 132.5M
- IPO Year
- CKPT 2017
- CRNC N/A
- Fundamental
- Price
- CKPT $3.00
- CRNC $13.66
- Analyst Decision
- CKPT Strong Buy
- CRNC Hold
- Analyst Count
- CKPT 2
- CRNC 8
- Target Price
- CKPT $13.50
- CRNC $7.61
- AVG Volume (30 Days)
- CKPT 998.1K
- CRNC 15.6M
- Earning Date
- CKPT 11-12-2024
- CRNC 02-06-2025
- Dividend Yield
- CKPT N/A
- CRNC N/A
- EPS Growth
- CKPT N/A
- CRNC N/A
- EPS
- CKPT N/A
- CRNC N/A
- Revenue
- CKPT $47,000.00
- CRNC $331,504,000.00
- Revenue This Year
- CKPT N/A
- CRNC N/A
- Revenue Next Year
- CKPT $172,016.02
- CRNC $13.35
- P/E Ratio
- CKPT N/A
- CRNC N/A
- Revenue Growth
- CKPT N/A
- CRNC 12.57
- 52 Week Low
- CKPT $1.38
- CRNC $2.34
- 52 Week High
- CKPT $4.50
- CRNC $27.50
- Technical
- Relative Strength Index (RSI)
- CKPT 38.29
- CRNC 58.16
- Support Level
- CKPT $3.07
- CRNC $12.66
- Resistance Level
- CKPT $3.42
- CRNC $14.90
- Average True Range (ATR)
- CKPT 0.21
- CRNC 2.73
- MACD
- CKPT -0.03
- CRNC -0.28
- Stochastic Oscillator
- CKPT 4.94
- CRNC 30.52
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About CRNC Cerence Inc.
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.